$1.69 -0.02 (-1.18%)

Tenaya Therapeutics, Inc. Common Stock (TNYA)

Tenaya Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious, life-threatening genetic diseases, particularly those affecting the heart. Founded with the aim of transforming the treatment landscape, Tenaya leverages advanced genetics, stem cell biology, and disease modeling to identify and develop innovative medicines. The company's approach centers on understanding the underlying mechanisms of genetic disorders and translating this knowledge into targeted therapies to improve patient outcomes.

🚫 Tenaya Therapeutics, Inc. Common Stock does not pay dividends

Company News

Tenaya Therapeutics Presents Interim Data from MyClimbâ„¢ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
GlobeNewswire Inc. • Tenaya Therapeutics • August 31, 2025

Tenaya Therapeutics shared interim data from its MyClimb study on pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy, revealing significant risks and disease progression patterns across different genetic inheritance groups.

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Benzinga • Avi Kapoor • March 15, 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results. Blend Labs posted quarterly loss of 9 cents per share, in-line with market estimates of 9 cents per share. The company�...

Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
Zacks Investment Research • Zacks Equity Research • February 26, 2024

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

5 Russell 2000 Stocks Poised to Give the Large Caps a Run for Their Money
Investing.com • Investing.com • February 6, 2024

The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch • MarketWatch • January 6, 2024

A more selective small-cap index has consistently outperformed the Russell 2000